Regeringen vill ge pengar till läkemedelsbolag för att skynda på utvecklingen av antibiotika som står emot motståndskraftiga bakterier köpa inderal receptfritt Svenska materialet kan bli alternativ till antibiotika.
Microsoft word - grantsdec06.doc
GRANTS: DECEMBER 2006
UNWILLING TO PRESCRIBE NEEDED MEDICATION?
EMERGENCY DEPT BY CHRONIC PAIN PATIENTS TO
BARRIERS TO TREATMENT, ABUSIVE BEHAVIORS AND PSYCHOLOGICAL FACTORS
VOLATILE ANESTHETIC ACTION IN VERTEBRATE LOCOMOTOR SYSTEMS
POTASSIUM CHANNELS BY NITRIC OXIDE AND NEUROPROTECTION
DYNAMIC ANALYSES OF LEARNING IN BEHAVIORAL EXPERIMENTS
A COMPARISON OF THE ADDICTION LIABILITY OF HYDROCODONE AND
DEMOGRAPHIC, SOCIOECONOMIC AND GENETIC FACTORS IN SLE
STEM CELLS AS MEANS FOR DECREASING BREAST
MOLECULAR ANALYSIS OF OCULAR LENS BEADED
DEVELOPMENT OF THE OLFACTORY CONNECTIONS
ANALYZING MYC FUNCTION IN NEURAL DEVELOPMENT AND CANCERS
SPERM GLYCINE RECEPTORS AND ZONA-INITIATED EXOCYTOSIS
CTR FOR DEVELOPMENT OF ANTISPERM CONTRACEPTIVES
THE FUNCTIONS OF TENEURINS IN THE DEVELOPING VISUAL
UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE
INTEGRATING MEDICINE INTO BASIC SCIENCE AT UC
RESEARCH FACILITIES IMPROVEMENT PROJECT FOR
STATEWIDE INITIATIVE TO DISSEMINATE END OF LIFE
IMPROVE SHARED DECISION MAKING: PROSTATE
NICOTINIC RECEPTORS ALTER GENE EXPRESSION
TOBACCO SMOKE INDUCED LUNG TUMORS IN A/J MICE?
keratinocyte galvanotaxis and wound healing
AN OPEN LABEL STUDY TO EVALUATE WHETHER A
PATIENTS TREATED WITH EFALIZUMAB IS SAFE AND
INTEGRINS AND PRO-INFLAMMATORY SECRETORY
INTEGRINS AND PRO-INFLAMMATORY SECRETORY
AUDICOR TECHNOLOGY FOR RAPID DIAGNOSIS AND INITIAL TREATMENT OR
TESTING AND INITIAL STRATEGY FOR TREATMENT
PREDICTING CERVICAL SPINE INJURY IN CHILDREN
gun watch: reducing gun violence through evidence
AMERICAN CANCER SOCIETY MENTORED RES SCHOLAR
SONG BROWN PRIMARY CARE PHYSICAN ASSISTANT
AND FAMILY NURSE PRACTITIONER TRAINING PROG
PHYSICIAN ASSISTANT TRAINING IN PRIMARY CARE
EL CAMINO A LA SALUD: CANCER PRIORITIES IN THE
CANCER PRIORITIES IN THE LATINO POPULATION
surveillance strategies following treatment for
following treatment for cervical INTRAEPITHELIAL
LUNAR: A 12 WEEK, RANDOMIZED, OPEN LABEL,
3 ARM, PARALLEL GROUP, MULTICENTER, PHASE IIIB
STUDY COMPARING THE EFFICACY AND SAFETY OF
ATORVASTATIN 80MG IN SUBJECTS WITH ACUTE CORONARY SYNDROMES
TELMISARTAN ALONE AND IN COMBINATION WITH
promote reverse electrical remodeling of the atria? (01-
ASSESSMENT OF CHEST PAIN IN THE EMERGENCY
CLIRPATH EXCIMER LASER SYSTEM TO ENLARGE
TAXUS IV-SR: TREATMENT OF DE NOVO CORONARY
DISEASE USING A SINGLE PACLITAXEL-ELUTING STENT
PERCUTANEOUS CORONARY INTERVENTION (ICE-IT)
DOUBLE BLIND TRIAL TO ASSESS TAXUS PACLITAXEL-
ELUTING CORONARY STENTS, SLOW-RELEASE FORMULATION
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO
CONTROLLED STUDY TO EVALUATE THE EFFICACY
AND SAFETY OF AD5FGF-4 IN PATIENTS WITH STABLE
FACTOR: FLOWCARDIA’S APPROACH TO CHRONIC
TOTAL OCCLUSION RECANALIZATION: CLINICAL INVESTIGATIONAL
WATCHMAN LEFT ATRIAL APPENDAGE FILTER SYSTEM
US IDE PILOT CLINICAL STUDY INVESTIGATIONAL
APPENDAGE SYSTEM FOR EMBOLIC PROTECTION IN
PATIENTS WITH ATRIAL FIBRILLATION: US IDE
PIVOTAL CLINICAL STUDY INVESTIGATIONAL PLAN
STUDY OF THE EVALVE CARDIOVASCULAR VALVE REPAIR SYSTEM (CVRS)
TRIAL OF THE MEDTRONIC ENDEAVOR DRUG (ABT-578)
ELUTING CORONARY STENT SYSTEM VERSUS THE TAXUS
PACLITAXEL ELUTING CORONARY STENT SYSTEM
IN DE NOVO NATIVE CORONARY ARTERY LESIONS
A PHASE I-II, MULTICENTER, RANDOMIZED, DOUBLE
STUDY TO EVALUATE THE SAFETY AND POTENTIAL
EFFICACY OF SINGLE, INCREASING DOSES OF TG100-115 IN SUBJECTS
INTERVENTION FOR ACUTE ST ELEVATION MYOCARDIAL
MITOCHONDRIAL CALCIUM ENTRY THROUGH VDAC
THERAPY OPTIMIZATION WITH V-V TIMING IN HEART FAILURE PATIENTS
H7T-MC-TAAL: A COMPARISON OF CS-747 AND CLOPIDOGREL IN
AND NATIONAL COMMUNITY CARDIOVASCULAR DISEASE
FOR IMPLANTABLE CARDiOVERTER DEFIBRILLATOR THERAPY
WIRELESS, AUTOMATIC, MOBILE MONITORING FOR
RISK REDUCTION EVAL WITH ICD IMPLANTATIONS
THE APPROACH STUDY: A PHASE III, MULTICENTER,
ROSIGLITAZONE VERSUS GLIPIZIDE ON THE PROGRESSION OF
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC
SAME AND FOLATE DEFICIENCY IN ALCOHOLIC MICROPIGS
MRI DEVELOPMENT OF OMX: A STRUCTURED ILLUMINATION MICROSCOPE
SYSTEM WITH SUB-100 NM SPATIAL RESOLUTION FOR
LUTEINIZING HORMONE SECRETION MECHANISMS
peptide surface modification to prevent stent blockage
ADVANCED ERCP TECHNIQUES: A PILOT STUDY FROM A UNIVERSITY
PLUS REBETOL VS. PEG-INTRON 1UG/KG/WK PLUS
REBETOL VS. PEGASYS 180 UG/KG/WK PLUS COPEGUS
IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH
CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1
A PROSPECTIVE MULTICENTER, OPEN LABEL, COMPARATIVE EFFICACY
STUDY OF PEGASYS PLUS COPEGUS IN TREATMENT OF
NAIVE LATINO PATIENTS WITH CHRONIC HEPATITIS
C - GENETYPE 1, AS COMPARED TO TREATMENT
NAIVE NON LATINO CAUCASIAN PATIENTS WITH CHRONIC HEPATITIS C
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO
CONTROLLED TRIAL TO EVALUATE THE EFFICACY,
SAFETY AND TOLERABILITY OF RIFAXIMIN 550 MG BID
PHASE II, RANDOMIZED, MULTICENTER, DOUBLE
INHIBITOR PRODRUG (RO4588161) WHEN GIVEN
IN COMBINATION WITH PEGASYS WITH OR WITHOUT COPEGUS VERSUS
THE CURRENTLY APPROVED COMBINATION OF PEGASYS
PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1
BLIND, STUDY EVALUATING THE EFFICACY (AS
MEASURED BY SUSTAINED VIROLOGICAL RESPONSE)
AND SAFETY OF 360 UG INDUCTION DOSING OF
PEGASYS IN COMBINATION WITH HIGH COPEGUS DOSES IN TREATMENT OF
GENOTYPE 1 VIRUS INFECTION OF HIGH VIRAL
TITER AND BASELINE BODY WEIGHT GREATER THAN OR
OXIDATIVE INJURY IN LIVER CARCINOGENESIS
ASSESSING PREVENTION AND EARLY INTERVENTION NEEDS THROUGH
A CULTURALLY TARGETED APPROACH TO MEDICATION
ELDERLY PATIENTS WITH IDIOPATHIC ANEMIA OF
CONTROLLED STUDY TO ASSESS CHANGES IN PHYSICAL FUNCTION IN
ELDERLY PATIENTS WITH ANEMIA OF A CHRONIC
HETEROGENEITY OF TREATMENT EFFECTS IN THE
improving care for comorbid physical and mental illnesses
PARATHYROID HORMONE 1-34 (HPTH 1-34) REVERSE GLUCOCORTICOID INDUCED
GLUCOCORTICOIDS AND RISEDRONATE AFTER BONE
STRENGTH BY REGULATING EXPRESSION OF GENES
pArallel arm, placebo controlled, double blind
multiple dose study to investigate the safety and efficacy of rn624 in patients
SAFETY AND TOLERABILITY OF AMG 162 IN THE
the breast cancer experience of slavic women
FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 COMPARED TO
PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POST
A PHASE III RANDOMIZED STUDY OF EXEMESTANE
POSTMENOPAUSAL WOMEN AT INCREASED RISK OF DEVELOPING BREAST
CARDIOVASCULAR HEALTH STUDY - TRANSITION PHASE
CONTROLLED TRIAL TO IMPROVING PALLIATIVE CARE THROUGH
LONGITUDINAL WEB-BASED ACTIVATION OF RESIDENTS
CENTER STUDY OF THE EFFICACY AND SAFETY OF
NATEGLINIDE AND VALSARTAN IN THE PREVENTION OF DIABETES
CONTROLLED EVALUATION OF CLOPIDOGREL PLUS
IRBESARTAN, FOR THE PREVENTION OF VASCULAR EVENTS, IN PATIENTS WITH
evaluate the accuracy of anti-fibrin humanized
monoclonal antibody (di-dd3b6/22-80b3) fab protein
fragment conjugated with technetium in the detection
INVOLVING PATIENTS WITH IDIOPATHIC VENOUS
A PHASE II, MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE
B ANTIBODY (MONOCLONAL ANTI-BLYS ANTIBODY) IN
SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (LBSL02) AND A
MULTICENTER, OPEN LABEL, CONTINUATION TRIAL OF
FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF
MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
PROFESSIONAL USE AT THE POINT OF CARE CLINICAL
ANTICOAGULANT THERAPY (RE-LY) COMPARING THE
EFFICACY AND SAFETY OF TWO BLINDED DOSES
WARFARIN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLIC
EVENTS IN PATIENTS WITH NON VALVULAR ATRIAL
THE ONCOTYPE DX ASSAY FOR ESTROGEN RECEPTOR
POSITIVE, NODE NEGATIVE BREAST CARCINOMA: DOES
IT IMPACT ON PHYSICIAN ADJUVANT TREATMENT
BLIND, STRATIFIED, PLACEBO CONTROLLED, MULTICENTER, 3-ARM TRIAL
A PHASE I/II STUDY OF TWO DIFFERENT SCHEDULES OF
BORTEZOMIB (PS-341) AND PEMETREXED IN ADVANCED
SOLID TUMORS, WITH EMPHASIS ON NON-SMALL
RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF
PEMETREXEL) ALONE FOR TREATMENT OF RECURRENT
OR REFRACTORY NON-SMALL CELL LUNG CANCER
CISPLATIN VERSUS GEMZAR (GEMCITABINE) AND
CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL
phase i/ii study of erlotinib (tarceva) and cetuximab
(erbitux) in advanced solid tumors, with emphasis on
PHASE II OPEN LABEL, MULTICENTER CLINICAL
STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF SNS-
595 IN PATIENTS WITH ADVANCED SMALL CELL
AND DNA REPAIR GENES TO ENHANCE RADIATION
43-9006 IN PATIENTS WITH PLATINUM-TREATED
572016 IN LOCALLY ADVANCED OR METASTATIC
REAGENTS AND ASSAYS FOR STRUCTURE BASED PATHOGEN DETECTION
THERAPEUTIC TARGETING AGENTS FOR OVARIAN
A PHASE III RANDOMIZED STUDY OF BAY 43-9006 IN
NATIONAL, DOUBLE BLIND, RANDOMIZED PHASE III
PLACEBO PLUS PREDNISONE IN PATIENTS WITH HORMONE REFRACTORY
BONE TURNOVER IN METASTATIC PROSTATE CANCER
DECISION MAKING, PATIENT CAREGIVER DISTRESS AND
CULTURALLY APPROPRIATE CARE IN CANCER PATIENT POPULATION
CORRELATIVE STUDIES FOR CLINICAL PROTOCOL P7097: A PHASE II STUDY OF AZD
2171 IN PATIENTS WITH RECURRENT SMALL CELL
CORRELATIVE STUDIES FOR CLINICAL PROTOCOL P7077:
A RANDOMIZED PHASE II TRIAL OF SEQUENTIAL
VERSUS CONCURRENT DOCETAXEL AND PS-341 IN
PREVIOUSLY TREATED NON SMALL CELL LUNG CANCER
HYPOXIA INDUCED PROTEINS AS LUNG CANCER BIOMARKERS
A RANDOMIZED, TWO WAY BLINDED CROSSOVER DESIGN STUDY TO
WITH A FULL LENGTH RECOMBINANT FACTOR VIII
PREPARATION FOLLOWED BY AN OPEN LABEL TRIAL OF THE SAFETY AND EFFICACY
blinded crossover study to determine the
pharmacokinetics and safety of a single intravenous
infusion of bay 79-4980 recombinant factor viii formulated with sucrose
reconstituted with 9% pegylated liposome diluent
(bay 79-4979) in previously treated patients with severe
a randomized two way blinded crossover study to
determine the pharmacokinetics and safety
of a single intravenous infusion of bay 79-4980
recombinant factor viii formulated with sucrose
reconstituted with 9% pegylated liposome diluent (bay 79-4979) in previously
treated patients with severe hemophIlia a
PREVENTING BLEEDING DISORDER COMPLICATIONS
A MULTICENTER, SINGLE ARM, OPEN LABEL STUDY TO
EVALUATE THE SAFETY AND EFFICACY OF SINGLE AGENT
RELAPSED OR REFRACTORY AGGRESSIVE NON HODGKIN LYMPHOMA
DOXIL-MMY-3001: A RANDOMIZED CONTROLLED STUDY OF DOXIL/CAELYX
AND VELCADE OR VELCADE MONOTHERAPY FOR THE
A PHASE III, MULTICENTER, 52-WEEK, RANDOMIZED, DOUBLE BLIND, PLACEBO
CONTROLLED STUDY OF THE CLINICAL EFFICACY AND
HYDROXYUREA THERAPY IN PATIENTS WITH SICKLE
CELL DISEASE WHO HAVE HAD TWO ACUTE SICKLE RELATED PAINFUL CRISES
CELL CTR CLINICAL TRIALS CONSORTIUM (CSCC CTC)
IMMUNOGENICITY OF THE MERCK TRIVALENT ADENOVIRUS SEROTYPE 5
HIV-1 GAG/POL/NEF VACCINE IN A PRIME BOOST
IMMUNOGENICITY OF A 3-DOSE REGIMEN OF THE
MRKAD5 HIV-1 TRIGENE AND THE MRKAD6 HIV-1 TRIGENE VACCINES ALONE
SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF
HUMAN IMMUNDEFICIENCY VIRUS TYPE 1 GAG DNA
BUFFERED SALINE OR WITH ALUMINUM PHOSPHATE, FOLLOWED BY AD5 HIV-1,
IMMUNOGENICITY OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE I (HIV-1) GAG DNA FORMULATED WITH
ADENOVIRUS SEROTYPE 5 HIV-1 VACCINE (AD5 HIV-1 GAG) IN A PRIME/BOOST
MULTICENTER, DOUBLE BLINDED, PHASE IV STUDY
COMPARING THE SAFETY AND EFFICACY OF PEGASYS
180 UG PLUS COPEGUS 1000 (75< KG) OR 1200 MG (>75 KG) TO THE
CURRENTLY APPROVED COMBINATION OF PEGASYS
180 UG PLUS COPEGUS 800 MG IN INTERFERON-NAIVE
PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1
VIRUS INFECTION CO-INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
STAPHYLOCOCCUS AUREUS (MRSA) INFECTION AMONG
MINORITY AIDS INITIATIVE, STREET OUTREACH DIRECTLY OBSERVED
PREVENTION INTERVENTION STRATEGIES WITH HIV
INFECTED PERSONS AS SEEN IN FOUR DIFFERENT
(TELBIVUDINE) VERSUS LAMIVUDINE IN ADULTS
WITH COMPENSATED CHRONIC HEPATITIS B: NV-
A PILOT I/II RANDOMIZED PLACEBO CONTROLLED
TRIAL TO ASSESS THE SAFETY AND EFFICACY OF
ANTIBODY TITERS IN PATIENTS WITH OR AT HIGH RISK FOR PROGRESSION TO
WEST NILE VIRUS ENCEPHALITIS OF MYELITIS
SAFETY AND EFFICACY OF SEROSTIM (MAMMALIAN
CELL DERIVED RECOMBINANT HUMAN GROWTH HORMONE, R-
HGH) IN THE TREATMENT AND MAINTENANCE OF
A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE
BLIND, ADJUVANT CONTROLLED TRIAL TO EVALUATE THE SAFETY AND
IMMUNOGENICITY OF AN HIV CTL MULTI-EPITOPE
AND GM-CSF GIVEN TO HIV-1 POSITIVE ADULTS
CALIFORNIA RES CTR FOR THE BIOLOGY OF HIV IN
CLINICAL AND LABORATORY PROTOCOL FOR THE STUDY
OF GUAVA TECHNOLOGY EASY CD4 INSTRUMENT SYSTEM AND GUAVA EASY
AN OPEN LABEL TRIAL WITH TMC125 IN HIV-1 INFECTED
SUBJECTS, WHO WERE RANDOMIZED TO A TMC125
TMC125 TRIAL AND WERE TREATED FOR AT LEAST 48
AN OPEN LABEL TRIAL OF TELBIVUDINE (LDT) IN
ADULTS WITH CHRONIC HEPATITIS B PREVIOUSLY
ELVUCITABINE VERSUS LAMIVUDINE ADMINISTERED ONCE DAILY
BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY
TO EVALUATE THE SAFETY AND ANTIRETROVIRAL
ACTIVITY OF MK-0518 VERSUS EFAVIRENZ IN TREATMENT NAIVE HIV
INFECTED PATIENTS, EACH IN COMBINATION WITH
CYSTEINE SULFENIC ACIDS: IMPLICATIONS FOR
THE EFFECT OF ETANERCEPT IN SUPPRESSION OF THE
LOW MOLECULAR WEIGHT UREMIC TOXINS PRODUCED
BY INFLAMMATORY OXIDATIVE PATHWAYS: THE EFFECTS OF
USING INTRAVENOUS INJECTIONS OF RO0503821
IN PATIENTS WITH CHRONIC KIDNEY DISEASE WHO ARE ON DIALYSIS
THE EFFECT OF ETANERCEPT TNFR:FC IN SUPPRESSION OF THE SYSTEM
INFLAMMATORY RESPONSE IN HEMODIALYSIS PATIENTS
ATHEROSCLEROSIS AND INFLAMMATION IN DIALYSIS
CLINICAL RES NETWORK FOR THE TREATMENT OF
ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME
A LONG TERM STUDY OF AMBRISENTAN IN PULMONARY ARTERIAL
HYPERTENSION SUBJECTS HAVING COMPLETED AMB-
HEMODYNAMIC EFFECTS OF UT-15C SR IN SUBJECTS
VISION C200-006: A RANDOMIZED, PLACEBO CONTROLLED STUDY TO
EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION
OF INHALED ILOPROST IN PATIENTS WITH PULMONARY
hemodynamics in patients with pulmonary arterial hypertension associated with
EFFICACY AND SAFETY OF ORAL UT-15C SUSTAINED
RELEASE TABLETS IN SUBJECTS WITH PULMONARY ARTERIAL
GENETICS IN SUBJECTS WITH PULMONARY ARTERIAL
PROTOCOL TDE-PH-302: A 12 WEEK, INTERNATIONAL,
MULITCENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED
COMPARISON OF THE EFFICACY AND SAFETY OF
ORAL UT-15C SUSTAINED RELEASE TABLETS IN
TDE-PH-304: AN OPEN LABEL EXTENSION TRIAL OF
UT-15C IN PATIENTS WITH PULMONARY ARTERIAL
placebo controlled, phase iii study of the efficacy of
interferon gamma-1b in patients with idiopathic pulmonary fibrosis
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE III,
THREE ARM STUDY OF THE SAFETY AND EFFICACY OF
RANDOMIZED, DOUBLE BLIND STUDY TO EVALUATE
THE SAFETY AND EFFECTIVENESS OF THE EXHALE DRUG ELUTING
GENOMIC RESPONSES OF THE LUNGS TO TOBACCO
PROTECTIVE ROLE FOR NITRIC OXIDE IN AIRWAY
ATTENUATION OF MUCOUS CELL METAPLASIA BY RAD
A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE
3 TRIAL TO ASSESS THE SAFETY OF TOBRAMYCIN
HOMEOSTASIS PLAY A ROLE IN ENDOTHELIN MEDIATED ENDOTHELIAL
TRAINING IN COMPARATIVE LUNG BIOLOGY AND
IL-17 MEDIATED MUC GENE EXPRESSION IN AIRWAY
MURINE MODEL OF PRIMARY BILIARY CIRRHOSIS
PATHOGENESIS OF PRIMARY BILIARY CIRRHOSIS
B CELL AND AMA RESPONSE IN PATIENTS WITH PRIMARY
XENOBIOTICS of PRIMARY BILIARY CIRRHOSIS
EPIGENETICS OF X-LINKED GENES IN PBC: DOES X
JUICE CONSTITUENTS ON THE ANTIBODY RESPONSE
PRENATAL AND NEONATAL BIOLOGICAL MARKERS FOR
A SCREEN FOR POTENTIAL EARLY BIOMARKERS OF
NOVEL MEMBRANE PROTEINS IN SYNAPSE FORMATION
transmembrane proTeins that regulate synaptic
BLOCKERS AS NEW THERAPEUTICS FOR MULTIPLE SCLEROSIS
DRUG FOR RESTENOSIS, TRANSPLANT REJECTION
A MULTICENTER STUDY TO EVALUATE THE EFFECT OF
PARASPINAL MUSCULATURE USING HIGH RESOLUTION
LUMBAR DEGENERATIVE DISC DISEASE TREATED
WITH ANTERIOR TENSION BAND SYSTEM (ATB) WITH
SEALANT SYSTEM AS AN ADJUNCT TO SUTURED DURAL REPAIR WITH
RANDOMIZED, CONTROLLED CLINICAL TRIAL COMPARING
MOBI-C PROSTHESIS TO CONVENTIONAL ANTERIOR CERVICAL DISCECTOMY AND
DEGENERATIVE DISC DISEASE IN THE CERVICAL
INFIX INTERBODY FUSION STUDY - CHART AUDIT
POSTOPERATIVE EPIDURAL FIBROSIS AND RELATED
A RANDOMIZED, RATER-BLINDED, MULTICENTER,
PARALLEL GROP STUDY COMPARING THE EFFICACY
AND SAFETY OF BETASERON 250MG SUBCUTANEOUSLY EVERY OTHER DAY WITH
PER WEEK IN RELAPSING REMITTING MULTIPLE
SCLEROSIS PATIENTS PREVIOUSLY TREATED WITH
MULTICENTER, PHASE III STUDY IN PATIENTS WITH RELAPSING-REMITTING
multicenter, randomized, double-blind, placebo
controlled, parallel group study to evaluate the effect
of early glatiramer acetate treatment in delaying the conversion to clinically
definite multiple sclerosis of subjects presenting with a
A 24-WK, RANDOMIZED, DOUBLE BLIND, PARALLEL
ANTIBODY ABT-874 IN SUBJECTS WITH MULTIPLE SCLEROSIS WITH A 24-WK
BLIND, PARALLEL GROUP STUDY TO COMPARE THE
EFFICACY, TOLERABILITY AND SAFETY OF COPAXONE TO THAT OF HIGH DOSE
INTERFERON IN THE TREATMENT OF RELAPSING
OPEN LABEL, RANDOMIZED, STUDY OF REBIF 44MCG
SUBCUTANEOUS INJECTION COMPARED WITH COPAXONE 20MG
ADMINISTERED DAILY BY SUBCUTANEOUS INJECTION
STUDY TO EVALUATE THE SAFETY AND TOLERABILITY
OF NATAZILUMAB IN SUBJECTS WITH MULTIPLE SCLEROSIS WHO HAVE
COMPLETED STUDIES C-1801, C-1802 OR C-1803
BLIND, RANDOMIZED STUDY COMPARING THE COMBINED
USE OF INTERFERON BETA-1A AND GLATIRAMER
ACETATE TO EITHER AGENT ALONE IN PATIENTS WITH
RELAPSING MULTIPLE SCLEROSIS (COMBIRX-PHASE III)
CANNABIS FOR SPASTICITY IN MULTIPLE SCLEROSIS:
OPEN LABEL EXTENSION STUDY TO EVALUATE THE
SAFETY, TOLERABILITY AND ACTIVITY OF ORAL
FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS WHO
MULTICENTER, EXTENSION STUDY TO EVALUATE THE
FOLLOWING RE-INITIATION OF DOSING IN MULTIPLE
SCLEROSIS SUBJETS WHO HAVE COMPLETED STUDY C-1801, C-1802 OR C-1803
MULTICENTER, PLACEBO CONTROLLED, PARALLEL
GROUP STUDY COMPARING THE EFFICACY AND SAFETY
OF 0.5 MG AND 1.25 MG FINGOLIMOD (FTY720) ADMINISTERED ORALLY
ONCE DAILY VERSUS PLACEBO IN PATIENTS WITH
GROUP, DOUBLE BLIND STUDY TO COMPARE THE
EFFICACY, TOLERABILITY AND SAFETY OF GLATIRAMER ACETATE
INJECTION 40 MG/ML TO THAT OF GLATIRAMER
TRAINING IN CLINICAL TRIALS: ESSENTIAL FOR A CAREER IN MULTIPLE
CALIFORNIA NON-AD DIAGNOSTIC RELIABILITY
STUDY CL-758007, A PHASE III STUDY OF THE EFFICACY
AND SAFETY OF ALZHEMED IN PATIENTS WITH MILD TO
CONTROLLED, MULTIPLE ASCENDING DOSE SAFETY,
TOLERABILITY, PHARMACOKINETIC, PHARMOCODYNAMIC AND
IMMUNOGENICITY TRIAL OF AAB-001 IN PATIENTS WITH
STROKE INCIDENCE AND RISK FACTORS IN A TRI-
HETEROGENEITY OF MILD COGNITIVE IMPAIRMENT
FUNCTIONAL EFFECTS OF CONGENITAL MYASTHENIA
PREDICTION OF EVERYDAY FUNCTION DEMENTIA
OLIGODENDROGLIAL DEATH BY THE BC1 FAMILY
USE OF ALLELE-SPECIFIC SMALL INTERFERING RNAS
FOR TREATMENT OF SLOW CHANNEL CONGENITAL
MORPHOLOGIC CHANGES INDUCED BY SOMAN AT THE HUMAN NEUROMUSCULAR
CELLULAR MECHANISMS OF MENTAL RETARDATION
REGULATION OF NMDAR TRAFFICING AND FUNCTION
PROTEINS IN EARLY STAGES OF NEURAL DEVELOPMENT: POSSIBLE IMPLICATIONS
AGING BRAIN: VASCULAR, ISCHEMIA AND BEHAVIOR -
PATIENTS WITH FAMILIAL TOURETTE’S SYNDROME
PLACEBO CONTROLLED STUDY OF AGGRENOX VS. CLOPIDOGREL AND
A MULTICENTER, DOUBLE BLIND, PARALLEL GROUP,
(MIRAXION) IN PATIENTS WITH MILD TO MODERATE
IS GLUTATHIONE OR ANOTHER SULFHYDRYL-REDUCING AGENT THE
TRIGGER OF AUTOIMMUNE MYASTHENIA GRAVIS?
CLINICAL ACTIVITY AND SAFETY OF TWO DOSE
LEVELS OF SUBCUTANEOUS A6 IN PATIENTS WITH ASYMPTOMATIC CA125
PRIMARY PERITONEAL CARCINOMA AFTER FIRST
CALIFORNIA EXPANDED AFP SCREENING PROGRAM
MID-LIFE AGING AND URINARY INCONTINENCE IN
a multicenter, randomized, open label study to compare
subconjunctival injections of 100ug cat-152 human anti-
tgfB2 monoclonal antibody with an intraoperative
sponge application of 5-fluorouracil following first
FOCUSED DELIVERY OF LASER ENERGY TO THE EYE USING ADAPTIVE OPTICS
AGE RELATED EPIGENETIC GENE SILENCING IN THE RPE
STUDY OF THE STENT TRABECULAR BYPASS MICRO STENT IN
POSTERIOR JUXTASCLERAL ADMINISTRATIONS OF ANECORTAVE ACETATE FOR
DEPOT SUSPENSION (15MG OR 30MG) VERSUS SHAM
STUDY "A" OR STUDY "B") AT RISK FOR DEVELOPING
SIGHT-THREATENING CHOROIDAL NEOVASCULARIZATION
(CNV) DUE TO EXUDATIVE AGE-RELATED MACULAR
a six month, phase III multicenter, masked
randomized, sham-controlled trial (with six month open
label extensioin) to assess the safety and efficacy of
700 mg and 350 mg dexamethasone posterior segment drug delivery
system in the treatment of patients with macular edema
following central retinal vein occlusion of branch-vein
STUDY TO EVALUATE THE SAFETY AND TOLERABILITY
OF RANIBIZUMAB IN SUBJECTS WITH SUBFOVEAL
SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE
A PHASE IIIB, SINGLE MASKED, MULTICENTER,
RANDOMIZED STUDY TO EVALUATE THE SAFETY AND
TOLERABILITY OF RANIBIZUMAB IN NAIVE AND PREVIOUSLY TREATED
LOWERING AGENTS REDUCE APOPTOSIS AND TISSUE
SPECIFIC CHOLESTEROL DEPOSITS INDUCED IN MICE FED
FOR PATIENTS COMPLETING STUDY B7A-MC-MBCM
MULTICENTER, MASKED, RANDOMIZED SHAM-CONTROLLED TRIAL TO
DELIVERY SYSTEM (DEX PS DDS) APPLICATOR SYSTEM
IN THE TREATMENT OF PATIENTS WITH DIABETIC
CORNEAL METALLOPROTEINASE MATRIX INTERACTIONS
THE EFFECTS OF EMBRYONIC STEM CELLS ON A MURINE MODEL OF
A RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP,
THE SAFETY AND EFFICACY OF ASI-001A 0.5 UG/DAY
AND ASI-001A 0.2 UG/DAY FLUOCINOLONE ACETONIDE
INTRAVITREAL INSERTS TO SHAM INJECTION IN SUBJECTS WITH DIABETIC
OSTEOCYTE SCLEROSTIN RESPONSE TO MECHANICAL
FOR ENHANCING THE DELIVERY OF RECOMBINANT
HUMAN BONE MORPHOGENETIC PROTEIN-2 IN A NON HUMAN
REMODELING SIMULATION TO STUDY THE MECHANICAL
ADAPTABILITY AND FATIGUE RESISTANCE OF BONE
INTRAOSSEOUS VASCULAR ANATOMY OF THE HUMAN
ROLE OF TENSIN GENES IN TISSUE REGENERATION AND
LONG TERM EFFECTS OF BISPHOSPHONATE THERAPY ON BONE
EFFECTS OF JOINT REPLACEMENT ON CARDIOVASCULAR FITNESS,
LIKE MOLECULE (IL-17RL) IN PROSTATE CANCER AND
ARTICULAR CARTILAGE SURFACE REGENERATION
A BIOMECHANICAL STUDY OF REPAIR TECHNIQUES FOR SPONDYLOLYTIC
PATHOLOGY & LABORATORY MEDICINE ELLIS,
VASCULATURE, ISCHEMA AND BEHAVIOR - CORE C
PATHOLOGY & LABORATORY MEDICINE GREGG,
CHEMOPREVENTION IN A MOUSE MODEL FOR DCIS
DEATH REGISTRY SYSTEM - TRAINING, MAINTENANCE AND OPERATIONS (CA-
clinical studies in nutrition and metabolism
the use of novel amyloid binding ligands for anti-
PRECISION, ACCURACY AND CLINICAL EFFECTIVENESS
performance evaluation of hemocue glucose rt system
CLINICAL EVAL OF GOLD (ACCU-CHEK PERFORMA) GLUCOSE MONITORING
FUNGINEMIA WITH RAPID NUCLEIC ACID TESTING:
mecp2, methyl deficiency and hepatic tumorigenesis
ASSESSMENT OF VITAMIN B12 BIOAVAILABILITY FROM BEEF
GENE THERAPY TO LOWER SERUM HOMOCYSTEINE IN A MOUSE MODEL
FUNCTIONAL CHARACTERIZATION OF THE AMINOTERMINUS OF SIV
A PHASE III RANDOMIZED, MULTINATIONAL STUDY,
DOUBLE BLINDED FOR THE IMMUNOGENICITY AND
CONSISTENCY EVALUATION OF 3 HIB-MEDCYTT VACCINE
LOTS AND SINGLE BLINDED AND CONTROLLED FOR THE
EVALUATION OF SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS
HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA
GAIN INSIGHT INTO HIV AND AIDS IN CHILDREN
NUTROPIN AQ, NUTROPIN AND NUTROPIN DEPOT IN CHILDREN WITH GROWTH
FAILURE DUE TO CHRONIC RENAL INSUFFICIENCY OR
BIOACTIVITY AND VITAMINS IN FLASH HEATED BREASTMILK
cases for molecular epidemiology of childhood leukemia
HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1
CEREBRAL EDEMA IN PEDIATRIC KETOACIDOSIS
EMPHASIS ON NEURODEVELOPMENTAL DISORDERS
UNIVERSITY CTR FOR EXCELLENCE IN DEVELOPMENTAL
DISABILITIES, EDUCATION, RES AND SERVICE
IMPROVING THE CARE OF ACUTELY ILL AND INJURED
CHILDREN IN RURAL EMERGENCY DEPARTMENTS WITH TELEMEDICINE
2006-07 CYSTIC FIBROSIS FOUND ACCREDITATION AND FUNDING
AN ETHNOGRAPHIC STUDY OF ADOLESCENT DATING VIOLENCE:
COMMUNITY PARTNERSHIPS WITH PEDIATRICIANS FOR
PROJ TO RURAL FIRST AMERICANS VIA TELEHEALTH
ANNUAL GENE THERAPY SYMPOSIUM FOR LUNG AND BLOOD DISEASES
MESENCHYMAL STEM CELLS FOR FETAL GENE DELIVERY
CHARACTERIZATION USING LASER TWEEZERS RAMAN
IMMUNOTHERAPY FOR DIABETIC COMPLICATIONS
POSITIONAL CLONING OF OBESITY GENES FROM
RAPID ISOLATION OF DIET-RESPONSIVE OBESITY
CHILDREN’S ONCOLOGY GROUP (COG) RES PROG
CNMC0601 RANDOMIZED STUDY OF DAILY VS. HIGH
DOSE WEEKLY PREDNISONE THERAPY IN DUCHENNE
rehabilitation res & training ctr in neuromuscular
disease: enhancing health, function, and quality of life
regulation of the synaptic localization of the nachr
MECHANISMS OF RELEASE AND ROLE OF T CELL EXOSOMES IN
BLOOD-BRAIN BARRIER IN CEREBRAL ISCHEMIA
K-C1 COTRANSPORTERS IN RAT NERVOUS SYSTEM
CFTR VS. CA-ACTIVATED CHLORIDE CHANNELS IN
evaluation of face processing with psychophysiological and
eeg indices of negative affect in children with autism or
HEALTH DISPARITIES IN PATIENTS WITH CHRONIC
PSYCHOTIC DISORDERS VERSUS NON-PSYCHOTIC
TRACKING THE COURSE OF MATHEMATICAL LEARNING
brain based measures for treatment development of
CHILD AND ADOLESCENT PSYCHIATRY AT UC DAVIS
BLIND, PARALLEL GROUP, PLACEBO CONTROLLED
PHASE IIIB STUDY OF THE EFFICACY AND SAFETY OF QUETIAPINE FUMARATE
(SEROQUEL) IMMEDIATE RELEASE TABLETS IN DAILY
DOSES OF 400 MG AND 800 MG COMPARED WITH
MULTICENTER, OPEN LABEL PHASE IIIB STUDY OF THE SAFETY AND TOLERABILITY
OF QUETIAPINE FUMARATE (SEROQUEL) IMMEDIATE
RELEASE TABLETS IN DAILY DOSES OF 400 MG AND 800
MG IN CHILDREN WITH BIPOLAR I DISORDER AND
BLIND, CONTROLLED STUDY OF TWO FIXED ORAL DOSES OF ARIPIPRAZOLE IN THE
TOLERABILITY STUDY OF FLEXIBLE DOSE ORAL
ADOLESCENT PATIENTS WITH SCHIZOPHRENIA AND CHILD AND ADOLESCENT
PATIENTS WITH BIPOLAR I DISORDER, MANIC OR
STUDY OF ESCITALOPRAM IN PEDIATRIC PATIENTS
BLIND, PLACEBO CONTROLLED STUDY OF TWO FIXED ORAL DOSES OF
ARIPIPRAZOLE (10MG AND 30MG) IN THE TREATMENT
OF CHILD AND ADOLESCENT PATIENTS, AGES 10-17,
WITH BIPOLAR 1 DISORDER, MANIC OR MIXED EPISODE
AGGRESSIVE BEHAVIOR IN FRAGILE X SYNDROME
GAZE PATTERNS IN AUTISM ACROSS THE FIRST TWO
INTERDISCIPLINARY TRAINING FOR AUTISM RESEARCHERS
DEFINITION AND DEVELOPMENT OF THE PHENOTYPE OF AUTISM
COGNITIVE SEQUELAE OF METHAMPHETAMINE ABUSE
NUMERICAL DEFICITS ACROSS MULTIPLE GENETIC
STAR): PILIPINA BREAST CANCER SUPPORT GROUP OUTREACH (AANCART)
IMPACT OF INTERPRETERS ON CANCER CARE ACCESS AND DELIVERY FOR THAI
SWAN SLEEP STUDY II-UC DAVIS/ KAISER SITE
STUDY OF WOMEN’S HEALTH ACROSS THE NATION III
METHODS DEVELOPMENT FOR EXPOSURE RELATED BEHAVIORS
EARLY CHILDHOOD DEVELOPMENT AND PCB EXPOSURES IN SLOVAKIA
POLYBROMINATED DIPHENYL ETHERS AS A POTENTIAL
costs of occupational injury and illness
NEEDS ASSESSMENT FOR THE UC DAVIS SCHOOL OF
PATIENTS RECEIVING THERAPEUTIC RADIATION
HYBRID NUCLEAR X-RAY PROJECTION SYSTEM FOR
INTRAVENOUSLY ADMINISTERED NONIONIC CONTRAST MEDIA
technique and patient outcomes in laparoscopic
A NOVEL THERAPY FOR PANCREAS AND PROSTATE
DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER,
DOSE SELECTION STUDY OF AD2/HYPOXIA INDUCIBLE
USING A SPRAY APPLICATOR IN SUBJECTS UNDERGOING AUTOLOGOUS SKIN
GRAFTING FOLLOWING BURN OR TRAUMATIC skin
EFFICACY OF NEOADJUVANT XELOX THERAPY FOR
GALECTIN LEVELS AND APOPTOSIS IN KELOID AND NORMAL FIBROBLASTS
SACRAMENTO TRAUMA CTR ALCOHOL INTERVENTION
PKC ISOENZYMES AND DIABETIC MICROVASCULAR
MICROVASCULAR BARIER DYSFUNCTION IN THERMAL
NEUTROPHIL DEPENDENT REGULATION OF VENULAR
CANCER CTR SUPPORT GRANT- CURE SUPPLEMENT
OF H2 RELAXIN AS A FACILITATOR OF ANDROGEN
har alterations and androgen-independant
PACKER severe allergy treatment Plan nursing Office: tel. 718 250-0259 Fax: 718 250-0292 [email protected] _______________________________________________________________________________student’s last name, First name, middle name ________________________________________________________________________________________ complete Physician’s instructions. sign and date all areas.
Using Business Intelligence to Discover New Market OpportunitiesUsing Business Intelligenceto Discover New MarketOpportunitiesJanice FratesCalifornia State University Long BeachMany companies have customers of which theyBusiness Intelligence, Marketing, Competition,are only minimally aware, people who started using agiven product while seeking a solution for an appar-ently unrelated need. Th